Update on lymphocyte-activation gene 3 (LAG-3) in cancers: from biological properties to clinical applications
10.1097/CM9.0000000000001981
- VernacularTitle:Update on lymphocyte-activation gene 3 (LAG-3) in cancers: from biological properties to clinical applications
- Author:
Lishu ZHAO
1
;
Hao WANG
;
Kandi XU
;
Xinyue LIU
;
Yayi HE
Author Information
1. Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China
- Keywords:
Lymphocyte-activation gene 3 (LAG-3);
Immune checkpoint;
Cancer;
Immunotherapy
- From:
Chinese Medical Journal
2022;135(10):1203-1212
- CountryChina
- Language:Chinese
-
Abstract:
Immunotherapy that targets checkpoints, especially programmed cell death protein 1 and programmed cell death ligand 1, has revolutionized cancer therapy regimens. The overall response rate to mono-immunotherapy, however, is limited, emphasizing the need to potentiate the efficacy of these regimens. The functions of immune cells are modulated by multiple stimulatory and inhibitory molecules, including lymphocyte activation gene 3 (LAG-3). LAG-3 is co-expressed together with other inhibitory checkpoints and plays key roles in immune suppression. Increasing evidence, particularly in the last 5 years, has shown the potential of LAG-3 blockade in anti-tumor immunity. This review provides an update on the biological properties and clinical applications of LAG-3 in cancers.
